Sign In
Buy ERFSF
Eurofins Scientific Nante Earnings Calls
| Release date | Jan 29, 2026 |
| EPS estimate | $1.48 |
| EPS actual | $1.50 |
| EPS Surprise | 1.35% |
| Revenue estimate | 4.335B |
| Revenue actual | 4.327B |
| Revenue Surprise | -0.184% |
| Release date | Jun 30, 2025 |
| EPS estimate | $2.01 |
| EPS actual | $1.54 |
| EPS Surprise | -23.38% |
| Revenue estimate | 4.264B |
| Revenue actual | 4.253B |
| Revenue Surprise | -0.271% |
| Release date | Jul 22, 2025 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
| Release date | Dec 31, 2024 |
| EPS estimate | $1.54 |
| EPS actual | $0.99 |
| EPS Surprise | -35.78% |
| Revenue estimate | 3.678B |
| Revenue actual | 3.658B |
| Revenue Surprise | -0.547% |
Last 4 Quarters for Eurofins Scientific Nante
Below you can see how ERFSF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Dec 31, 2024 |
| Price on release | $52.46 |
| EPS estimate | $1.54 |
| EPS actual | $0.99 |
| EPS surprise | -35.78% |
| Date | Price |
|---|---|
| Dec 24, 2024 | $50.78 |
| Dec 26, 2024 | $52.80 |
| Dec 27, 2024 | $51.00 |
| Dec 30, 2024 | $49.49 |
| Dec 31, 2024 | $52.46 |
| Jan 02, 2025 | $51.62 |
| Jan 03, 2025 | $51.68 |
| Jan 06, 2025 | $51.13 |
| Jan 07, 2025 | $53.65 |
| 4 days before | 3.31% |
| 4 days after | 2.27% |
| On release day | -1.60% |
| Change in period | 5.65% |
| Release date | Jul 22, 2025 |
| Price on release | $73.59 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 16, 2025 | $72.00 |
| Jul 17, 2025 | $72.00 |
| Jul 18, 2025 | $72.50 |
| Jul 21, 2025 | $72.00 |
| Jul 22, 2025 | $73.59 |
| Jul 23, 2025 | $76.32 |
| Jul 24, 2025 | $76.88 |
| Jul 25, 2025 | $82.14 |
| Jul 28, 2025 | $77.36 |
| 4 days before | 2.21% |
| 4 days after | 5.13% |
| On release day | 3.71% |
| Change in period | 7.45% |
| Release date | Jun 30, 2025 |
| Price on release | $71.74 |
| EPS estimate | $2.01 |
| EPS actual | $1.54 |
| EPS surprise | -23.38% |
| Date | Price |
|---|---|
| Jun 24, 2025 | $68.72 |
| Jun 25, 2025 | $69.60 |
| Jun 26, 2025 | $73.61 |
| Jun 27, 2025 | $71.50 |
| Jun 30, 2025 | $71.74 |
| Jul 01, 2025 | $73.03 |
| Jul 02, 2025 | $71.01 |
| Jul 03, 2025 | $70.85 |
| Jul 07, 2025 | $70.49 |
| 4 days before | 4.40% |
| 4 days after | -1.75% |
| On release day | 1.80% |
| Change in period | 2.57% |
| Release date | Jan 29, 2026 |
| Price on release | $81.05 |
| EPS estimate | $1.48 |
| EPS actual | $1.50 |
| EPS surprise | 1.35% |
| Date | Price |
|---|---|
| Jan 23, 2026 | $85.17 |
| Jan 26, 2026 | $82.71 |
| Jan 27, 2026 | $85.00 |
| Jan 28, 2026 | $86.13 |
| Jan 29, 2026 | $81.05 |
| Jan 30, 2026 | $82.31 |
| Feb 02, 2026 | $80.55 |
| Feb 03, 2026 | $80.38 |
| Feb 04, 2026 | $81.66 |
| 4 days before | -4.84% |
| 4 days after | 0.758% |
| On release day | 1.55% |
| Change in period | -4.12% |
Eurofins Scientific Nante Earnings Call Transcript Summary of Q4 2025
Key points for investors: Eurofins reported a strong 2025: EPS grew ~24% and the group generated >€1bn of free cash flow (pre certain site investments). Management is midway through a 5-year transformation (hub-and-spoke, heavy digital/IT and automation investments) and expects to complete the major build-out by 2027. Reported and adjusted margins improved in 2025 with operating leverage accelerating in H2; management reiterates the objective of ~24% adjusted EBITDA by 2027 for the group (mature scope already near that level). CapEx remains elevated while the IT/digital investment peak is passing (management indicated ~€50m of IT CapEx tied to the digital programme), and guidance for gross CapEx is in the c.€400m range for the coming period. BioPharma showed mixed trends: product testing (core) is steady mid-single-digit, Discovery/genomics and agroscience remain soft but are expected to plateau with possible reacceleration (management points to potential material Central Lab/Bioanalysis contract awards that could ramp in H2 2026 and contribute materially thereafter). Synlab Spain integration has been dilutive in the short term (exceptional costs and margin dilution) but management expects cost takeout and value creation as integration completes (first phase mid-2026). Cash generation and balance-sheet strength allow continued M&A and shareholder returns; management has been active in share buybacks and flagged buybacks as an attractive use of capital given the board’s view that the shares are substantially undervalued versus peers/transaction multiples. Leverage policy remains 1.5–2.5x net debt / EBITDA target range. Key near-term risks noted: FX translation effects (profit mix skewed to North America), short-term Synlab dilution and integration costs, timing/phasing of BioPharma program awards, and residual service disruption from IT rollouts. Management expects operating leverage and margin expansion to continue into 2026–2027 and to deliver compounding EPS and free-cash-flow growth beyond 2027 as investments mature.
